Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma

Trial Profile

A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 14 May 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colon cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms AVANT
  • Sponsors Roche
  • Most Recent Events

    • 14 May 2018 Results (n=3451) assessing the predictive potential of TSR, by determining the effects on DFS and OS in patients with high-risk stage II and stage III colon cancer who received standard oxaliplatin-based chemotherapy with or without addition of bevacizumab, were published in the British Journal of Cancer.
    • 20 Jan 2018 Results from patients receiving adjuvant FOLFOX in MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials (n=7230) presented at the 2018 Gastrointestinal Cancers Symposium
    • 12 Sep 2017 Results evaluating the predictive potential of TSR on disease free survival (DFS) and overall survival (OS) (n=1212) presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top